Afatinib Genomic Landscape
The investigators propose to conduct a pilot feasibility study of single agent afatinib in patients with previously untreated metastatic EGFR (epidermal growth factor receptor) mutant adenocarcinoma of the lung (NSCLC = non-small cell lung cancer) with the sole purpose of characterizing the genomic landscape before afatinib and at the time of disease progression.
Checked against the public recordLast updated Mar 5, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Washington University School of Medicine
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria/Exclusion Criteria: * Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma * Presence of known sensitizing mutations in EGFR TK domain (exon 19 deletion and L858R) * Absence of known resistant mutations in the EGFR TK domain (T790M) * Consented to HRPO # 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma") * No prior treatment for this malignancy * No prior localized therapy to the biopsy site * Planned treatment with standard of care afatinib at 40 mg QD (daily) * Not pregnant or breastfeeding * At least 18 years of age
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Washington University School of MedicineSt Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2018. Always confirm current availability with the study team.